The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 4 Rheumatoid Arthritis Therapy Principles, & New Drug Info

4 Rheumatoid Arthritis Therapy Principles, & New Drug Info

July 19, 2018 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Tofacitinib, a rheumatoid arthritis drug.

Tofacitinib, a rheumatoid arthritis drug.
MOLEKUUL / science source

CHICAGO—Amid what she called a “dizzying array of choices” for rheumatoid arthritis (RA)—from anti-TNF and anti-IL6-receptor therapies to B cell depletion to new biosimilar options—disease treatment should still revolve around several basic concepts, an expert said at the ACR State-of-the-Art Clinical Symposium in April.

You Might Also Like
  • Cobra Therapy for Rheumatoid Arthritis
  • The Impact of Pharma Info vs. Neutral Info on Patients’ Drug Decisions
  • Rheumatoid Arthritis Therapy Update: What’s Changed & What’s the Same
Explore This Issue
July 2018
Also By This Author
  • Twitter Is Key Learning, Networking Tool for Rheumatologists

Joan Bathon, MD, chief of rheumatology at Columbia University in New York City, laid out four main principles clinicians should use to guide their choices as new therapies march onto the RA landscape.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

First, she said, early treatment should be the primary aim, to prevent damage and disability. “We want to start DMARD [disease-modifying anti-rheumatic drug] treatment as soon as you make the diagnosis—hopefully that’s within six weeks of either recognition of the symptoms or a definitive diagnosis,” she said.

Second, she said, “Treat hard.” In other words, treat patients with the maximum effective dose they can tolerate, with a rapid escalation of DMARDs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Third, patients should generally be treated with a combination of DMARDs, when appropriate, because combination therapy is consistently more effective than monotherapy. “One thing’s for sure,” Dr. Bathon said. “If your patient has bad prognostic signs … you want to think about combination therapy.” Those signs could include a very high number of swollen joints; exceptionally high erythrocyte sedimentation rates, C-reactive protein levels, rheumatoid factor or cyclic citrullinated peptides; or erosions at baseline.

Finally, treatment should have a goal in mind—ideally remission, but at least low disease activity, Dr. Bathon said.

Lessons Learned

Lessons from the 2007 BeST study on early RA remain highly relevant, she said.1 The study evaluated several approaches, including a series of monotherapies, a step-up approach to combination therapy, a combination as initial therapy or a methotrexate-infliximab start. In each arm, remission was the goal, and treatment had to change every three months if a Disease Activity Score 44 (DAS44) of 2.4 or lower wasn’t achieved.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Improvements in signs and symptoms were seen regardless of the therapy and strategy, although radiologic outcomes were better with early combination therapy than delayed combination therapy.

These results hold a crucial lesson, Dr. Bathon said. “Goal-directed therapy is really optimal,” she said.

A sensible treatment algorithm, she said, is to start with methotrexate monotherapy unless it’s contraindicated, and then add a second DMARD if the response isn’t good enough. If you see residual disease activity, she said, add a nonbiologic or a biologic therapy depending on the severity.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: 2018 State of the Art Clinical Symposium, Biosimilars, DMARDs, ILD, Interstitial Lung DiseaseIssue: July 2018

You Might Also Like:
  • Cobra Therapy for Rheumatoid Arthritis
  • The Impact of Pharma Info vs. Neutral Info on Patients’ Drug Decisions
  • Rheumatoid Arthritis Therapy Update: What’s Changed & What’s the Same
  • Factors that Influence Biologic Therapy Choices for Patients with Rheumatoid Arthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.